Centessa Pharmaceuticals Announces Significant Public Offering
BOSTON and LONDON — Centessa Pharmaceuticals plc (NASDAQ: CNTA), a company at the forefront of clinical-stage pharmaceuticals, is setting the stage for a remarkable opportunity. They are launching a public offering aimed at raising $150 million through American Depositary Shares (ADSs), where each share corresponds to one ordinary share.
Offering Details
The ADSs available in this offering will be issued directly by Centessa. In addition, the company intends to give underwriters a 30-day option to buy up to an extra $22.5 million worth of ADSs. Keep in mind that this offering is dependent on market conditions and other key factors, which means the final size and terms might change significantly.
Offering Management
A well-respected group of financial firms has been appointed as joint book-running managers for this public offering. This team includes prominent names like Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets. Their collective expertise will be critical to the success of this initiative.
Regulatory Process
The ADSs are being offered under a registration statement on Form S-3 that has been submitted to the U.S. Securities and Exchange Commission (SEC). This statement automatically became effective upon submission, facilitating a smoother process for both the company and potential investors. A preliminary prospectus supplement, along with the main prospectus, will be filed with the SEC soon. Investors can expect comprehensive information about this offering to be posted on the SEC's website.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals is committed to creating medicines that have the potential to significantly improve patient outcomes. Their research programs stand out, focusing on transformative treatments for hemophilia, innovative orexin agonists for narcolepsy and sleep disorders, as well as a promising immuno-oncology initiative based on their innovative LockBody® technology platform. Centessa aims to set new standards of care with each of its drug development efforts.
Contacting the Company
If you have any questions or need more information about this public offering, feel free to reach out to Kristen K. Sheppard, the Senior Vice President of Investor Relations. She can be contacted at investors@centessa.com.
Frequently Asked Questions
What is the aim of Centessa's new public offering?
The primary goal of the offering is to secure funding for the ongoing development of innovative therapies and to support various research initiatives.
How much funding is Centessa hoping to gather from this offering?
Centessa Pharmaceuticals is aiming to raise $150 million, and there’s an option for underwriters to secure an additional $22.5 million.
Who is overseeing the offering?
The offering is being managed by Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets.
What key programs is Centessa focused on?
Centessa's primary focus areas include developing treatments for hemophilia, solutions for narcolepsy, and advanced immuno-oncology therapies leveraging their LockBody® technology.
How can investors obtain more information about this offering?
Investors can access more details through the preliminary prospectus supplement that will be filed with the SEC, as well as through communications from the company directly.
